Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...

After a significant increase in 2023, Danish regions' expenses for subsidized medicines fell by 4.3% in 2024.

Patents require reliability so they can incentivize investments in new technologies, their primary though little-noticed ...

Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (“eRapa”) and Use Biodexa plans ...

If these laws proceed, they will restrict access to essential remedies and severely limit consumer choice,' says Canadian ...

Adcentrx Therapeutics Inc. and Adcentrx Therapeutics Shanghai Co. Ltd. have disclosed antibody-drug conjugates comprising a monoclonal antibody covalently bound to a cytotoxic drug through a linker.

In recent months China’s progress in artificial intelligence has stunned the world. A quieter yet equally significant shift ...

Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of ...

Additionally, Editas Medicine management will participate in the following upcoming investor conferences in March: To access the live webcasts of Editas Medicine’s presentations, please visit the ...

Biosimilars have also made inroads among generic suppliers. But development is lengthy and expensive. McKinsey estimates that it costs $100 to $300 million to develop a biosimilar and that it takes ...